Spyre Therapeutics (NASDAQ:SYRE) was upgraded by analysts at Jones Trading from a "hold" rating to a "buy" rating. They now have a $64.00 price target on the stock.
Spyre Therapeutics (NASDAQ:SYRE) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
Spyre Therapeutics (SYRE) Announces Positive Results for Phase 1 Study of SPY003 [Yahoo! Finance]
Spyre Therapeutics (NASDAQ:SYRE) was upgraded by analysts at
Wall Street
Can Spyre Therapeutics' (SYRE) Early SPY003 Results Mark a Turning Point in R&D Strategy? [Yahoo! Finance]